The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b study of ruxolitinib (Rux) + gemcitabine (G) ± nab-paclitaxel (N) in patients (pts) with advanced solid tumors.
 
Todd Michael Bauer
No Relationships to Disclose
 
Manish R. Patel
No Relationships to Disclose
 
Tina Evans Wood
No Relationships to Disclose
 
Thomas J. George
Consulting or Advisory Role - Bayer/Onyx; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst)
 
Fitzroy W. Dawkins
Employment - Incyte
 
Kimberli J. Brill
Employment - Galera Therapeutics (I); Incyte
Stock and Other Ownership Interests - Incyte
 
Yining Du
Employment - Incyte
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; OncoMed; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); NCI (Inst); Novartis (Inst); Regeneron (Inst); TRACON Pharma (Inst)